Nicolas Kiavue

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Trastuzumab deruxtecan as the first-line of chemotherapy in patients with a hormone receptor-positive, HER2-low or ultra-low metastatic or unresectable breast cancer

Trastuzumab deruxtecan as the first-line of chemotherapy in patients with a hormone receptor-positive, HER2-low or ultra-low metastatic or unresectable breast cancer

Journal: Bulletin du cancer

Published: October 12, 2025

Prognostic Significance and Predictive Value of Circulating Tumor Cells in Invasive Lobular Breast Carcinoma-An Exploratory Analysis of the STIC CTC Trial.

Prognostic Significance and Predictive Value of Circulating Tumor Cells in Invasive Lobular Breast Carcinoma-An Exploratory Analysis of the STIC CTC Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 19, 2025

Clinico-pathological factors predicting pathological response in early triple-negative breast cancer.

Clinico-pathological factors predicting pathological response in early triple-negative breast cancer.

Journal: NPJ breast cancer

Published: November 06, 2024

Benefits and limitations of circulating tumor DNA in breast cancer

Benefits and limitations of circulating tumor DNA in breast cancer

Journal: Bulletin du cancer

Published: October 11, 2024

Circulating tumor cells in breast cancer: clinical validity and utility.

Circulating tumor cells in breast cancer: clinical validity and utility.

Journal: NPJ breast cancer

Published: April 03, 2024

Elacestrant - ER+/HER2-, locally advanced, or metastatic breast cancer with an activating ESR1 mutation

Elacestrant - ER+/HER2-, locally advanced, or metastatic breast cancer with an activating ESR1 mutation

Journal: Bulletin du cancer

Published: February 29, 2024

Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases.

Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases.

Journal: Breast cancer (Tokyo, Japan)

Published: November 29, 2023

Overall Survival With Circulating Tumor Cell Count-Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial.

Overall Survival With Circulating Tumor Cell Count-Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: November 06, 2023

Microsatellite instability detection in breast cancer using drop-off droplet digital PCR.

Microsatellite instability detection in breast cancer using drop-off droplet digital PCR.

Journal: Oncogene

Published: July 22, 2022

Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical Trial.

Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical Trial.

Journal: JAMA oncology

Published: November 05, 2020

Clinical utility of circulating tumor cells: an update.

Clinical utility of circulating tumor cells: an update.

Journal: Molecular oncology

Published: September 18, 2020

Clinical Cutaneous Features of Patients Infected With SARS-CoV-2 Hospitalized for Pneumonia: A Cross-sectional Study.

Clinical Cutaneous Features of Patients Infected With SARS-CoV-2 Hospitalized for Pneumonia: A Cross-sectional Study.

Journal: Open forum infectious diseases

Published: July 23, 2020

Showing 1-12 of 17

Last Updated: 09/26/2026